

To,  
The Manager,  
Department of Corporate Services,  
**BSE Limited,**  
Phirozee Jeejeeboy Towers,  
Dalal Street, Fort,  
Mumbai – 400 001.  
**Scrip Code: 543963**

Dear Sir/Madam,

**Subject: Outcome of Board Meeting held today on Wednesday, 18<sup>th</sup> June, 2025 and Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015.**

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time, we wish to inform you that the Board of Directors of Shelter Pharma Limited (“the Company”) at their meeting held today i.e. Wednesday, 18<sup>th</sup> June, 2025, at the corporate office of the Company, 5<sup>th</sup> Floor, 501 Sakar 4, Opp. MJ Library Ashram Road Paldi, Ellisbridge, Ahmedabad, Ahmedabad City, Gujarat, India, 380006 have, *inter-alia*, considered and approved the following matters:

**1. Postponement of proposed Right issue.**

With respect to our disclosure dated 8<sup>th</sup> January, 2025 and 28<sup>th</sup> January, 2025, Board of Directors, after due deliberation, has decided to postpone the proposed Rights Issue, in light of evolving business priorities, execution timelines, and the current market environment.

**2. Raising of Funds through Issue of Convertible Equity Share Warrants/Any such other Convertible Securities.**

The Board had decided to raise funds by way of issuance of Convertible Equity Share Warrants/any such other Convertible Securities convertible into the Equity Shares of face value of Rs. 10/- each, for an aggregate amount not exceeding ₹ 50.00 Crores (Rupees Fifty Crores only) by way of Preferential Issue and Private Placement in one or more tranches, subject to such regulatory/statutory approvals as may be required and the approval of Shareholders of the Company.

The other details/information pertaining to the Preferential Issue/Private Placement of Convertible Equity Warrants/any such other Convertible Securities will be disclosed and submitted once the Board of Directors/duly constituted Committee will consider and approve the proposed Allottees, Number of Securities, Issue Price and other relevant details of such Issue and Allotment. Date of meeting of Board of Directors/duly constituted Committee for aforesaid purpose will be intimated separately within due course.

The Board shall take necessary steps to obtain Shareholder’s approval in respect of abovementioned item no: 02, as applicable via General Meeting/Postal Ballot within due course of time.

**Shelter Pharma Limited**

**Regd. Office & Works:** Shelternagar, Opp. Bus Station, Himatnagar-383001 Gujarat, India. Phone: +91 2772 240108/246995

**Corporate Office:** 5 TH Floor, 501 SAKAR 4, Opp. MJ Library Ashram Road Paldi, Ellisbridge, Ahmedabad, Gujarat -380006

Email: info@shelter.co.in

CIN: L24233GJ2007PLC051956

The Board Meeting commenced at 04:00 PM IST and concluded at 04:30 PM IST

Please note that in terms of the Company's Code of Conduct for Prohibition of Insider Trading and pursuant to Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, as amended, the trading window for trading in securities of the Company will open on Monday, June 23, 2025.

Kindly consider this and take on record as a requisite disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended from time to time.

The above information will be made available on the website of the company [www.shelter.in](http://www.shelter.in).

Kindly take the same on your good record and disseminate the same on your website.

Thanking you,  
Yours faithfully,  
**For Shelter Pharma Limited**

**Mr. Mustaqim Nisarahmed Sabugar**  
**Managing Director**  
**DIN: 01456841**

Date: 18<sup>th</sup> June, 2025  
Place: Ahmedabad